WaveMan
WaveMan · Company
ALUR · Allurion Technologies, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ALUR Allurion Technologies (ALUR) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001964979
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
1
13F, latest reported quarter

Allurion Technologies insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for ALLURION TECHNOLOGIES, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Davin Michael R
Director
SELL
2025-12-05 SECtraded 2025-12-04
1,606
$2.5K
-99.8%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Dec 3, 2025.
  • No other insider sold within 30 days.
  • 1 fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Davin Michael R sold about $2.5K of ALUR on Dec 4, 2025, the largest insider sale at the company on our record; 1 fund added in the latest 13F quarter.
Davin Michael R
Director
SELL
2025-12-05 SECtraded 2025-12-03
1,606
$2.4K
-99.8%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 1,606 shares held after it.
  • No other insider sold within 30 days.
  • 1 fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Davin Michael R sold about $2.4K of ALUR on Dec 3, 2025, the largest insider sale at the company on our record; 1 fund added in the latest 13F quarter.
Gaur Shantanu
Chief Executive Officer
BUY
2025-05-21 SECtraded 2025-05-19
8,000
$24.5K
-99.8%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Mar 28, 2025.
  • The trade is 50.0% of the 16,000 shares held after it.
  • No other insider bought within 30 days.
  • 1 fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Gaur Shantanu bought about $24.5K of ALUR on May 19, 2025; 1 fund added in the latest 13F quarter.
Gaur Shantanu
Chief Executive Officer
BUY
2025-04-01 SECtraded 2025-03-28
8,000
$26.8K
-99.8%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 8,000 shares held after it.
  • No other insider bought within 30 days.
  • 1 fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Gaur Shantanu bought about $26.8K of ALUR on Mar 28, 2025, the largest insider purchase at the company on our record; 1 fund added in the latest 13F quarter.
4 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
1 fund bought in last quarter
Revenue
-52.6% year over year
below 94% of Medical Devices
Margin
-188.8% net margin
below 85% of Medical Devices
Buybacks
no share repurchases reported
Short interest
0.1% of the float short (float per yahoo 2026-10-02) · 1.0 days to cover · settled 2026-10-15
below 93% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ALUR

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-99.8%12M
-100%-67%-33%+0%2026-072026-082026-082026-092026-092026-102026-10
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ALUR: institutional holders (13F)

13F holdings, latest reported quarter
SkyView Investment Advisors, LLC
45,174 sh
$1

Congress trades in ALUR

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ALUR planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ALUR mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Calamos Market Neutral Income Fund
$263 position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 1 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

ALUR financials

Revenue growth
-52.6%
XBRL, annual
Net margin
-188.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$12.6M
four quarters, 2025-04-01 to 2026-03-31
Net margin, TTM
-264.7%
net income over revenue, 2025-04-01 to 2026-03-31
Free cash flow, TTM
-$23.3M
operating cash flow minus capex, 2025-04-01 to 2026-03-31
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-0.64x
TTM operating cash flow over long-term 2026-03-31 plus current 2024-12-31 (15 months older than the period end)
Return on equity
n/a
average equity is zero or negative
Return on assets
-127.3%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
n/a
capital employed is zero or negative
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$30.8M
market value at close 2026-10-26 on 2026-05-12 shares, plus long-term 2026-03-31 plus current 2024-12-31 (15 months older than the period end), minus cash 2026-03-31
FCF yield
-15,533%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$15.2M$32.1M$53.5M$64.2M
Gross profit$9.6M$21.5M$41.5M$50.7M
Operating income-$30.2M-$50.2M-$79.1M-$32.0M
Net income-$28.8M-$7.2M-$82.8M-$37.7M
EPS (diluted)-3.81-3.20-59.38-37.75
Operating cash flow-$28.9M-$42.3M-$64.0M-$47.0M
Cash$5.4M$15.4M$38.0M$7.7M
Long-term debt$0$35.7Mn/a$3.1M
SEC XBRL, fiscal years, as known on 2026-10-28

ALUR Stock Sonar score 3/7 axes

Find similar shapesCompare

ALUR ranks highest on risk and compliance (78th percentile) and financial health (39th), and lowest on growth (6th), among Medical Devices peers.

Financial health
39
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-0.64x · 39 pct, sector of 150
Growth
6
Inputs
  • Revenue growth, YoY-52.6% · 6 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
78
Inputs
  • Short interest, % of float+0.1% · 89 pct, sector of 241
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+7.8% · 66 pct, sector of 198
4 not measured: Profitability, Insider conviction, Institutional and government, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; pre-tax loss, no effective tax rate to apply
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies